Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Novartis Pharmaceuticals42 enrolled

Overview

This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who complete CAMN107A1101 and obtained Informed concent by document Exclusion Criteria: * None

Novartis Investigative Site

Aichi, Japan

Number of Adverse Events

Time frame: 3 weeks

Best hematologic response rate and Best cytogenetic response rate.

Time frame: 3 years

Percentage of BCR-ABL genes transcript and mutation status of BCR-ABL

Time frame: 3 years

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.